Uniphyllin Continus
Uniphyllin Continus is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It works by relaxing the smooth muscle of the bronchial airways and reducing the airway's response to stimuli. The continuous-release mechanism provides stable therapeutic drug levels in the blood over 12 to 24 hours.
Dosage by Body Weight
Dosage must be individualized and titrated based on clinical efficacy, side effects, and serum theophylline monitoring. Tablets must be swallowed whole with fluid, and never chewed, crushed, or dissolved, as this destroys the sustained-release mechanism and can lead to rapid absorption and toxic levels.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Avoid use
- Tracking Notes
- Sustained-release tablets are not suitable for neonates or small infants due to swallowing hazards and highly variable drug clearance rates.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Avoid use
- Tracking Notes
- Infants in this weight category cannot safely swallow whole tablets. Crushing tablets to administer partial doses risks severe toxicity.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Avoid use
- Tracking Notes
- Oral liquid theophylline formulations or alternative asthma/COPD therapies should be used if treatment is necessary. Do not attempt to split tablets.
- Body Weight
- 11-15 kg
- Dose
- 100 mg (using appropriate pediatric formulations or half of a scored 200mg tablet if approved by physician)
- Frequency
- Every 12 hours
- Tracking Notes
- Only use if the child is capable of swallowing the tablet whole. Must be initiated under strict medical supervision with serum level monitoring.
- Body Weight
- 16-20 kg
- Dose
- 100 mg to 150 mg
- Frequency
- Every 12 hours
- Tracking Notes
- Dosing should target approximately 10-16 mg/kg/day divided into two doses. Monitor serum theophylline concentrations closely to maintain the therapeutic range of 10-20 micrograms/ml.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Avoid use | Sustained-release tablets are not suitable for neonates or small infants due to swallowing hazards and highly variable drug clearance rates. |
| 5-7 kg | Not recommended | Avoid use | Infants in this weight category cannot safely swallow whole tablets. Crushing tablets to administer partial doses risks severe toxicity. |
| 8-10 kg | Not recommended | Avoid use | Oral liquid theophylline formulations or alternative asthma/COPD therapies should be used if treatment is necessary. Do not attempt to split tablets. |
| 11-15 kg | 100 mg (using appropriate pediatric formulations or half of a scored 200mg tablet if approved by physician) | Every 12 hours | Only use if the child is capable of swallowing the tablet whole. Must be initiated under strict medical supervision with serum level monitoring. |
| 16-20 kg | 100 mg to 150 mg | Every 12 hours | Dosing should target approximately 10-16 mg/kg/day divided into two doses. Monitor serum theophylline concentrations closely to maintain the therapeutic range of 10-20 micrograms/ml. |
Formulation
Purpose
Maintenance treatment and prevention of bronchospasm associated with chronic asthma, chronic obstructive pulmonary disease (CO), chronic bronchitis, and emphysema.
Generic Name
TheophyllineScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.